Abnormality_NN
of_IN
Oct-1_NN
DNA_NN
binding_NN
in_IN
T_NN
cells_NNS
from_IN
Sjogren_NN
's_POS
syndrome_NN
patients_NNS
._.

Primary_JJ
Sjogren_NN
's_POS
syndrome_NN
-LRB-_-LRB-
SS_NN
-RRB-_-RRB-
is_VBZ
an_DT
autoimmune_JJ
rheumatic_JJ
disease_NN
characterized_VBN
by_IN
T_NN
cell_NN
hypoactivity_NN
._.

To_TO
understand_VB
the_DT
diminished_VBN
T_NN
cell_NN
response_NN
to_TO
activation_NN
signals_NNS
,_,
we_PRP
measured_VBD
nucleoprotein_NN
DNA-binding_JJ
activities_NNS
regulating_VBG
gene_NN
expression_NN
during_IN
T_NN
cell_NN
activation_NN
using_VBG
the_DT
electrophoretic_JJ
mobility_NN
shift_NN
assay_NN
._.

Peripheral_JJ
blood_NN
lymphocytes_NNS
from_IN
9\/19_CD
SS_NN
patients_NNS
were_VBD
found_VBN
to_TO
be_VB
defective_JJ
in_IN
their_PRP$
ability_NN
to_TO
bind_VB
an_DT
October_NN
sequence_NN
-LRB-_-LRB-
Oct-1_NN
-RRB-_-RRB-
._.

This_DT
Oct-1-binding_JJ
phenotype_NN
remained_VBD
stable_JJ
in_IN
culture_NN
for_IN
up_RB
to_TO
3_CD
days_NNS
prior_JJ
to_TO
activation_NN
._.

This_DT
abnormality_NN
was_VBD
not_RB
seen_VBN
in_IN
resting_VBG
T_NN
cells_NNS
nor_CC
T_NN
cells_NNS
from_IN
patients_NNS
with_IN
systemic_JJ
lupus_NN
erythematosus_NN
,_,
rheumatoid_JJ
arthritis_NN
-LRB-_-LRB-
RA_NN
-RRB-_-RRB-
,_,
or_CC
SS_NN
accompanied_VBN
by_IN
RA_NN
._.

The_DT
SS_JJ
Oct-1_NN
DNA-binding_JJ
abnormality_NN
correlated_VBD
significantly_RB
with_IN
an_DT
inability_NN
of_IN
cells_NNS
to_TO
exit_VB
the_DT
Gzero\/G1_NN
cell_NN
cycle_NN
phase_NN
when_WRB
stimulated_VBN
in_FW
vitro_FW
._.

Importantly_RB
,_,
nucleoprotein_NN
extracts_NNS
showing_VBG
decreased_VBN
DNA-binding_JJ
activity_NN
had_VBD
normal_JJ
amounts_NNS
of_IN
Oct-1_NN
proteins_NNS
as_IN
determined_VBD
by_IN
immunoprecipitation_NN
,_,
implying_VBG
a_DT
functional_JJ
defect_NN
in_IN
the_DT
Oct-1_NN
protein_NN
._.

Moreover_RB
,_,
defective_JJ
DNA_NN
binding_NN
was_VBD
corrected_VBN
by_IN
treatment_NN
with_IN
acid_NN
phosphatase_NN
._.

